promising treatments series
-
No “easy home runs”: Early Long COVID trials of Paxlovid and monoclonal antibodies failed, but the treatments still have potential
While three early clinical trials of these drugs did not find they led to health improvements for participants, further trials are getting more intentional in targeting viral persistence.
-
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation
Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways.
-
Clinical trials are testing cancer drug rapamycin for Long COVID and ME
Two clinical trials are currently underway in the U.S. to evaluate the effect of rapamycin on Long COVID and myalgic encephalomyelitis (ME) — one at Mount Sinai’s Cohen Center for Recovery from Complex Chronic Illness and another at Simmaron Research.
-
Berlin Cures’ failed Long COVID clinical trial yields lessons on study design
After advertising a potential Long COVID “cure” in its novel drug, called BC 007 (rovunaptabin), the German start-up Berlin Cures abruptly concluded its phase II clinical trial with a brief press release in November 2024 announcing the study was unsuccessful. The Sick Times spoke with study participants and outside experts and found that, while some…
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance